Deutsche Bank Ag\ Akero Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 335,618 shares of AKRO stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

335,618

Previous 326,047 2.94%

Holding current value

$10.7 Million

Previous $7.65 Million 25.87%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$21.45 - $29.34 $205,297 - $280,813	9,571 Added 2.94%	335,618 $9.63 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $12,963 - $17,430	-708 Reduced 0.22%	326,047 $7.65 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $2.43 Million - $4.26 Million	136,544 Added 71.79%	326,755 $8.25 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $905,984 - $4.01 Million	79,612 Added 71.98%	190,211 $4.44 Million
Q3 2023 Nov 09, 2023	SELL	$41.19 - $52.25 $2.63 Million - $3.34 Million	-63,951 Reduced 36.64%	110,599 $5.59 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $12.7 Million - $19.6 Million	-345,025 Reduced 66.41%	174,550 $8.15 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $3.42 Million - $4.62 Million	91,892 Added 21.49%	519,575 $19.9 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $13.9 Million - $22.7 Million	414,957 Added 3260.7%	427,683 $23.4 Million
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $20,675 - $69,359	-2,037 Reduced 13.8%	12,726 $433,000
Q2 2022 Aug 11, 2022	SELL	$8.0 - $15.01 $14,144 - $26,537	-1,768 Reduced 10.7%	14,763 $139,000
Q1 2022 May 13, 2022	SELL	$12.97 - $22.26 $21,270 - $36,506	-1,640 Reduced 9.03%	16,531 $234,000
Q4 2021 Feb 11, 2022	SELL	$19.87 - $26.24 $373,476 - $493,207	-18,796 Reduced 50.85%	18,171 $384,000
Q3 2021 Nov 04, 2021	SELL	$18.65 - $25.46 $20,104 - $27,445	-1,078 Reduced 2.83%	36,967 $826,000
Q2 2021 Aug 11, 2021	BUY	$24.81 - $32.35 $196,395 - $256,082	7,916 Added 26.27%	38,045 $944,000
Q1 2021 May 13, 2021	SELL	$24.04 - $34.19 $863,661 - $1.23 Million	-35,926 Reduced 54.39%	30,129 $874,000
Q4 2020 Feb 16, 2021	SELL	$25.12 - $29.89 $1.35 Million - $1.61 Million	-53,936 Reduced 44.95%	66,055 $1.7 Million
Q3 2020 Nov 12, 2020	BUY	$30.79 - $39.92 $1.95 Million - $2.53 Million	63,277 Added 111.57%	119,991 $3.7 Million
Q2 2020 Aug 13, 2020	BUY	$19.25 - $26.76 $1.04 Million - $1.45 Million	54,009 Added 1996.64%	56,714 $1.41 Million
Q1 2020 May 14, 2020	BUY	$12.8 - $27.05 $12,979 - $27,428	1,014 Added 59.96%	2,705 $57,000
Q4 2019 Feb 14, 2020	BUY	$17.37 - $27.27 $6,496 - $10,198	374 Added 28.4%	1,691 $37,000
Q3 2019 Nov 14, 2019	BUY	$16.89 - $29.88 $22,244 - $39,351	1,317 New	1,317 $29,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.49B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account